Roche breast cancer pill gets FDA priority review
Roche (OTCQX:RHHBY) reported that the US FDA accepted, under Priority Review, its New…
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease…
Roche Stock Falls as Breast Cancer Drug Fails Trial Goals
In a significant setback, Roche’s shares suffered a steep drop exceeding 7% at one point on Monday…
CERAN wrap: Roche phase III BC win seals thesis, boosts Olema
Roche AG’s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor…
Giredestrant demonstrates efficacy in early-stage breast cancer
Roche has reported positive Phase III data for its selective estrogen receptor degrader (SERD) giredestrant across multiple stages…